| Popis: |
Background: Lack of representation in genomic databases limits the generalizability of study findings, predictive models, and therapeutics. In cancer, the development of nearly 75% of cancer drugs have been informed by genomic data,1 yet there is persistent lack of diversity of genomic testing databases that inform clinical trials and lead to drug approval.2,3 The PROFILE project at Dana-Farber Cancer Institute (DFCI) is available to all adult cancer patients, offering free genomic testing for inclusion in their genomic database. Herein, we describe the enrollment ratios in PROFILE delineated by demographic group and cancer type. Methods: We conducted a cross-sectional analysis of the prevalence of PROFILE enrollment 7/8/2011 – 1/1/2022. Over this time period 177,788. Enrollment processes vary in each DFCI disease center, but all solid tumor patients are meant to be approached for enrollment around the time of their first visit. The electronic health record was queried to identify demographics, which are collected by registration staff at intake. Queried demographics included gender, age ( Citation Format: Nadine Jackson McCleary, Ellana K. Haakenstad, Bridget Neville, Arrien A. Bertram, Wendy Loeser, Joseph Grider, Andea Kruse, Alissa Gentile, Olga Kozyreva, Pedro Sanz-Altamira, Christopher Lathan, Michael J. Hassett, Ethan Cerami, Annette S. Kim, Marios Giannakis, R. Coleman Lindsley, Neal I. Lindeman, William C. Hahn, Janina Longtine, Barrett Rollins, Levi Garraway, Bruce E. Johnson. REAL variance in genomic testing by sex, age, race, ethnicity, and language: PROFILE database 7/2011 - 1/2022 [abstract]. In: Proceedings of the 15th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2022 Sep 16-19; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2022;31(1 Suppl):Abstract nr C070. |
